Penserra Capital Management LLC Grows Stock Position in Mirum Pharmaceuticals, Inc. $MIRM

Penserra Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 242.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,479 shares of the company’s stock after purchasing an additional 18,746 shares during the quarter. Penserra Capital Management LLC’s holdings in Mirum Pharmaceuticals were worth $1,941,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MIRM. Comerica Bank boosted its holdings in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. AQR Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after acquiring an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after acquiring an additional 1,720 shares during the last quarter. Caxton Associates LLP purchased a new stake in Mirum Pharmaceuticals in the first quarter worth $217,000. Finally, Empowered Funds LLC grew its stake in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after acquiring an additional 5,120 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Citizens Jmp boosted their price target on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. Evercore restated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Morgan Stanley raised their target price on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $107.25.

Mirum Pharmaceuticals Trading Up 2.3%

MIRM opened at $100.47 on Friday. The firm’s fifty day moving average is $83.26 and its two-hundred day moving average is $74.05. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $105.74. The firm has a market cap of $5.16 billion, a PE ratio of -116.82 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business’s revenue was up 47.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.30) EPS. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 3,143 shares of the firm’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $302,325.17. Following the completion of the transaction, the chief operating officer owned 23,286 shares of the company’s stock, valued at approximately $2,239,880.34. This trade represents a 11.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $132,621.93. Following the completion of the transaction, the chief financial officer directly owned 42,127 shares of the company’s stock, valued at approximately $3,931,712.91. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 45,136 shares of company stock worth $4,352,029. 14.36% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.